Evidence map›Paper›PMID 36895557›Full record

ArticleFrontiers in immunology2023

Delivery of spike-RBD by bacterial type three secretion system for SARS-CoV-2 vaccine development.

Yuchen Zhou, Jing Qu, Xiaomeng Sun, Zhuo Yue, Yingzi Liu, Keli Zhao, Fan Yang, Jie Feng, Xiaolei Pan, Yongxin Jin and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Yuchen ZhouState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Jing QuDepartment of Pathogen Biology, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
Xiaomeng SunState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Zhuo YueState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Yingzi LiuIntervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China.
Keli ZhaoIntervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China.
Fan YangState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Jie FengState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Xiaolei PanState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Yongxin JinState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Zhihui ChengState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Liang YangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Un-Hwan HaDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, Republic of Korea.
Weihui WuState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Liang LiDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Fang BaiState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
Nankai University · CNState Key Laboratory of Medicinal Chemical BiologyPeking University Shenzhen Hospital · CNSouthern University of Science and Technology · CNKorea University · KRShenzhen Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 pandemic continues to spread throughout the world with an urgent demand for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a bacterial vector COVID-19 vaccine (aPA-RBD) that carries the gene for the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Live-attenuated strains of

Indexed as

COVID-19COVID-19 VaccinesAnimalsHumansMicePandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusType III Secretion SystemsCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Type III Secretion Systemsanti-virus immunitylive-attenuatedPseudomonas aeruginosaSARS-CoV-2 vaccinetype 3 secretion system (T3SS)

Identifiers

PMID36895557
PMCPMC9988893
OpenAlexW4321459411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.